What is the lowest GLP-1 dose that still holds your weight?

Key takeaways

Dr. Linda's take

You did the hard part. The weight came off, your labs moved in the right direction, and now a different worry has taken its place. Maybe the cost is unsustainable. Maybe the side effects are wearing on you. Maybe you simply do not want to be at a maximum amount forever. So you go looking for the number, the smallest weekly amount that would still hold everything in place, and you find a hundred confident answers that do not agree.

Here is what I would rather tell you than a tidy answer. That number has not been established in a trial. The research that exists asked a different question, and the labels hand dose selection to a prescriber's judgment on purpose. That is not a dead end. It means the answer is a conversation and a period of watching rather than a figure you can look up, and knowing exactly which question the evidence answered is what lets you have that conversation as an equal.

Is there a proven lowest dose that still holds your weight?

No, and it is worth being precise about why. To establish a lowest effective maintenance amount, a study would need to take people who had already lost weight, divide them into several groups at different reduced amounts, and follow them long enough to see which groups held their result. That is not the design the major published trials used.

What they used instead was a withdrawal design. Everyone reaches a full maintenance amount, then one group continues and the other switches to placebo. That answers whether continuing matters, and it answers it with real force. It does not speak to how much is enough.

What did the withdrawal trials actually test?

Three trials shape most of what is known, and reading their designs closely is the whole point here. The large withdrawal trials compared continuing treatment at a full maintenance dosage against switching to placebo, which tells you a great deal about stopping and almost nothing about tapering, and that stay-or-stop decision is the subject of our guide on maintenance dosing versus stopping.

In the STEP 4 trial, participants who reached the 2.4 mg weekly semaglutide maintenance dosage after a 20-week run-in were randomized to continued semaglutide or a switch to placebo for 48 weeks. With continued semaglutide, mean body weight change from week 20 to week 68 was -7.9% compared with a gain of 6.9% with the switch to placebo. The people who continued kept going down. The people who switched to placebo went back up.

The STEP 1 trial extension followed people after treatment ended entirely. From week 0 to week 68, mean weight loss was 17.3% with semaglutide, and following treatment withdrawal participants regained 11.6 percentage points of lost weight by week 120. The authors concluded that one year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss.

The tirzepatide trial ran the same style of test. Participants enrolled in an open-label lead-in period received a once-weekly subcutaneous maximum tolerated dosage of 10 mg or 15 mg of tirzepatide for 36 weeks, and at week 36 they were randomized to continue receiving tirzepatide or switch to placebo for 52 weeks. The mean percent weight change from week 36 to week 88 was -5.5% with tirzepatide compared with a gain of 14.0% with placebo.

Now notice the design detail that matters most for your question. In every one of those trials, the comparison was a full maintenance amount against nothing at all. Not one of them compared a full amount against a reduced one. So when someone quotes a specific smaller number that holds weight, they are not citing this research, because this research did not test it.

What do the labels say about maintenance dosages?

This is where people are often surprised, because the labels are less rigid than the internet suggests.

The prescribing information for semaglutide, sold as Wegovy, states that the maintenance dosage for weight reduction in adults is either 1.7 mg or 2.4 mg, with 2.4 mg recommended, injected subcutaneously once weekly. That same label instructs prescribers to consider treatment response and tolerability when selecting the maintenance dosage.

The prescribing information for tirzepatide, sold as Zepbound, states that for weight reduction and long-term maintenance the recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly. That label also states that if patients do not tolerate a maintenance dosage, a lower maintenance dosage should be considered.

Read carefully, those are approved options that a prescriber selects, and the framing is explicitly about response and tolerability. Neither label claims that a lower option will preserve a result achieved at a higher one. That distinction is small on the page and large in real life. An approved lower option is not the same thing as a proven step-down strategy.

Why is a smaller amount not simply a smaller version of the same effect?

Because losing weight and holding weight may not be the same job. During active loss, these medicines are working against appetite and intake. During maintenance, the body is pushing back with its own counter-regulatory signals, and how much medicine it takes to blunt that push is genuinely not established. It could turn out that less is sufficient once the losing phase is over. It could also turn out that the same amount is needed. Nobody has published the head-to-head study that would settle it.

What the withdrawal data does show is that removing the medicine entirely allows substantial regain, and that the regain builds across months rather than appearing in a week. That timeline is useful. It means a change made with a prescriber can be observed over a reasonable window, with a plan for what happens if the trend turns. Our explainer on what causes regain covers the biology of that push in more detail.

One more thing worth saying plainly. You will find confident specific numbers online presented as the settled maintenance answer. Treat any specific number offered as established with real skepticism, because the trial that would establish it has not been published.

What can you bring to a conversation with your prescriber?

You do not need the answer. You need the right questions and a few things worth tracking, and that is entirely within reach.

Start with why you want a change, whether cost or side effect burden, since the reason often points to a different solution than the one you assumed. Then agree in advance on what you will watch and for how long, on a weight trend measured across months rather than day to day, and on what would count as a signal to revisit. Return of strong food preoccupation is one many people notice before the scale moves.

Protecting a result also depends on more than the number on a syringe. Regain after full withdrawal is well documented and unfolds over months rather than overnight, which is why any dose conversation is watched over time, and our overview of step-down plans walks through how clinicians structure that window. Adequate protein and resistance training also matter for keeping the lean tissue that supports your metabolic rate. If you are still deciding whether this class of treatment fits your health picture at all, our eligibility quiz is a straightforward first step.

The bottom line

There is no published trial answer to the lowest amount that still holds a result, because the studies everyone cites compared a full maintenance amount against stopping, not against a smaller one. The labels do offer more than one approved maintenance option, chosen by a prescriber based on response and tolerability, but an approved lower option is not evidence that it preserves weight lost at a higher one. What the evidence establishes clearly is that stopping altogether allows most of the loss to return over about a year. So the useful move is not hunting for a number online. It is bringing your actual reason for wanting a change to the person who manages your care, agreeing on what you will watch, and giving the plan enough time to show you the truth.

Frequently asked questions

Has any trial found the lowest dose that maintains weight loss?

Not as of now. The major studies used a withdrawal design in which everyone reached a full maintenance amount and then either continued or switched to placebo. In every one of those trials, the comparison was a full maintenance amount against nothing at all. That design cannot identify a minimum effective amount.

How much weight comes back if treatment stops completely?

A substantial share of it, over roughly a year. The authors concluded that one year after withdrawal of once-weekly subcutaneous semaglutide 2.4 mg and lifestyle intervention, participants regained two-thirds of their prior weight loss. The mean percent weight change from week 36 to week 88 was -5.5% with tirzepatide compared with a gain of 14.0% with placebo.

Do the labels allow a lower maintenance dosage?

They list more than one approved option. The prescribing information for semaglutide, sold as Wegovy, states that the maintenance dosage for weight reduction in adults is either 1.7 mg or 2.4 mg, with 2.4 mg recommended, injected subcutaneously once weekly. The prescribing information for tirzepatide, sold as Zepbound, states that for weight reduction and long-term maintenance the recommended maintenance dosage is 5 mg, 10 mg, or 15 mg, injected subcutaneously once weekly.

Is a lower approved option the same as a proven maintenance strategy?

No. That same label instructs prescribers to consider treatment response and tolerability when selecting the maintenance dosage. Selection based on response and tolerability is a clinical judgment, not a finding that a smaller amount preserves a result achieved at a larger one.

References

1. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. PubMed PMID 33755728. https://pubmed.ncbi.nlm.nih.gov/33755728/ (Accessed 2026-07-20).
2. Wilding JPH, Batterham RL, Davies M, et al. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. PubMed PMID 35441470. https://pubmed.ncbi.nlm.nih.gov/35441470/ (Accessed 2026-07-20).
3. Aronne LJ, Sattar N, Horn DB, et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. PubMed PMID 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/ (Accessed 2026-07-20).
4. Novo Nordisk (2026). WEGOVY (semaglutide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b (Accessed 2026-07-20).
5. Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use - prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b (Accessed 2026-07-20).

---

*This article is general education and is not medical advice. It cannot tell you what is right for your body. Talk with a licensed clinician about your own situation.*

*Written and clinically reviewed by Dr. Linda Moleon, MD. Last reviewed 2026-07-21.*